CCND1 Gene Role in Aging | New Inflammation Findings

Rethinking a Classic Oncogene in Senescent Cells

Biological research recently revealed a surprising function for a gene long associated with cancer. Researchers at the Sanford Burnham Prebys Medical Discovery Institute found that the CCND1 gene, which encodes the protein cyclin D1, plays a distinct role in senescent cells. These are cells that have exited the cell cycle and no longer divide. While this gene is famous for driving unchecked cell replication in tumor environments, it also acts as a primary driver of chronic inflammation in aged tissues. This shift in understanding positions a known cancer target as a potential lever for managing age-related decline.

The research, published August 20, 2026, in the journal Nature Aging, challenges previous assumptions about cell cycle regulators. Peter Adams, a professor at the institute and the study's corresponding author, noted the contradiction. Scientists had observed high levels of cyclin D1 in non-proliferating senescent cells. These cells act as a protective mechanism against cancer by freezing in a stable state. But they also release inflammatory molecules that accumulate over time. The team suspected this protein contributed to these inflammatory secretions outside of its standard cycle-regulating tasks.

Uncovering the Inflammatory Connection

The team analyzed sequencing data from 14 publicly available datasets. They confirmed that the CCND1 gene appeared more frequently in senescent cells than many common markers used to identify them. Further experiments demonstrated that cyclin D1, working with a partner molecule called cyclin-dependent kinase 6, actively sustains the inflammatory tendencies of these cells. They do this by promoting DNA damage, which forces the cells to release harmful inflammatory signals. This specific state is known as the senescence-associated secretory phenotype, or SASP.

Testing this in a complex animal model yielded clear results. The researchers observed cyclin D1 accumulating in the livers of mice as they grew older. These liver cells showed a marked increase in the expression of inflammatory genes. To determine if this gene was truly responsible for the observed decline, the team created mice genetically unable to produce cyclin D1. The aged livers of these modified mice suffered less DNA damage and showed significantly lower levels of inflammatory gene expression compared to their normal counterparts.

Potential Therapeutic Pathways for Healthy Aging

The most practical finding emerged when the researchers applied a drug known as palbociclib. This medication is currently approved by the Food and Drug Administration to treat specific types of breast cancer. By blocking the interaction between cyclin D1 and cyclin-dependent kinase 6, the treatment mimicked the protective results observed in the genetically modified mice. The treated mice displayed reduced inflammation and improved physical function.

The team assessed these improvements through several metrics of frailty in the mice, such as motor coordination, gait quality, and sensory loss. Older mice receiving the drug outperformed the control group in these physical tests. These results suggest that targeting the cyclin D1-CDK6 interaction could help reduce the chronic inflammation that often accompanies the aging process. While the work is preliminary, it offers a path for repurposing existing cancer drugs to address age-related inflammatory diseases. Future studies will determine if these findings translate effectively to human physiology.